X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA ABBOTT INDIA NATCO PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 44.3 32.5 136.6% View Chart
P/BV x 22.6 8.1 278.4% View Chart
Dividend Yield % 0.5 0.8 61.2%  

Financials

 NATCO PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
ABBOTT INDIA
Mar-16
NATCO PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs8776,015 14.6%   
Low Rs4243,707 11.4%   
Sales per share (Unadj.) Rs223.41,236.9 18.1%  
Earnings per share (Unadj.) Rs31.1122.2 25.4%  
Cash flow per share (Unadj.) Rs40.3129.0 31.2%  
Dividends per share (Unadj.) Rs5.0035.00 14.3%  
Dividend yield (eoy) %0.80.7 106.8%  
Book value per share (Unadj.) Rs219.5521.2 42.1%  
Shares outstanding (eoy) m33.0721.25 155.6%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.93.9 74.1%   
Avg P/E ratio x20.939.8 52.6%  
P/CF ratio (eoy) x16.137.7 42.8%  
Price / Book Value ratio x3.09.3 31.8%  
Dividend payout %16.128.6 56.2%   
Avg Mkt Cap Rs m21,504103,296 20.8%   
No. of employees `000NA3.0 0.0%   
Total wages/salary Rs m1,1283,370 33.5%   
Avg. sales/employee Rs ThNM8,891.8-  
Avg. wages/employee Rs ThNM1,140.0-  
Avg. net profit/employee Rs ThNM878.3-  
INCOME DATA
Net Sales Rs m7,38926,284 28.1%  
Other income Rs m167504 33.1%   
Total revenues Rs m7,55626,789 28.2%   
Gross profit Rs m1,7933,665 48.9%  
Depreciation Rs m304144 210.8%   
Interest Rs m3668 4,521.0%   
Profit before tax Rs m1,2904,017 32.1%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3091,421 21.7%   
Profit after tax Rs m1,0272,596 39.6%  
Gross profit margin %24.313.9 174.0%  
Effective tax rate %23.935.4 67.7%   
Net profit margin %13.99.9 140.8%  
BALANCE SHEET DATA
Current assets Rs m3,68114,446 25.5%   
Current liabilities Rs m3,1234,725 66.1%   
Net working cap to sales %7.637.0 20.4%  
Current ratio x1.23.1 38.6%  
Inventory Days Days8951 174.1%  
Debtors Days Days5920 300.1%  
Net fixed assets Rs m7,6851,113 690.6%   
Share capital Rs m331213 155.6%   
"Free" reserves Rs m6,67010,808 61.7%   
Net worth Rs m7,25911,076 65.5%   
Long term debt Rs m9550-   
Total assets Rs m11,95716,241 73.6%  
Interest coverage x4.5497.0 0.9%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.6 38.2%   
Return on assets %11.716.0 72.7%  
Return on equity %14.223.4 60.4%  
Return on capital %20.736.3 57.0%  
Exports to sales %39.40.6 6,400.9%   
Imports to sales %5.712.6 45.1%   
Exports (fob) Rs m2,908162 1,799.4%   
Imports (cif) Rs m4213,322 12.7%   
Fx inflow Rs m3,445268 1,285.6%   
Fx outflow Rs m7033,927 17.9%   
Net fx Rs m2,743-3,659 -74.9%   
CASH FLOW
From Operations Rs m1,4402,514 57.3%  
From Investments Rs m-1,089-800 136.2%  
From Financial Activity Rs m-353-803 43.9%  
Net Cashflow Rs m-1912 -0.2%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 75.0 2.0%  
Indian inst/Mut Fund % 7.8 7.9 99.2%  
FIIs % 16.6 0.1 16,630.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.1 152.0%  
Shareholders   25,395 18,270 139.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   BIOCON LTD  CADILA HEALTHCARE  UNICHEM LAB  DR. DATSONS LABS  AJANTA PHARMA  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Share Markets in India End Flat; Cipla & Bharti Airtel Top Gainers(Closing)

Share markets in India ended flat ahead of key corporate results and as profit booking in index heavyweights capped gains.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

25 Things PM Modi Did Not Tell You About the Indian Economy(Vivek Kaul's Diary)

Oct 9, 2017

There are way too many data points out there which clearly show that all is not well with the Indian economy.

The Multibaggers that will Rise from the Ashes of Disruption(Smart Contrarian)

Oct 4, 2017

Of new age asset-light businesses and an Indian player that ticks all the right boxes.

Invest in a 'Haunted House' Stock and Make a Killing(The 5 Minute Wrapup)

Oct 7, 2017

You can make a killing by buying non-commodity business in a commodity industry

Nifty 50 Constituents Change...Once Again(Daily Profit Hunter)

Oct 4, 2017

Does it make sense to look at long term charts when the index constituents are changing frequently?

BSE IPO Index vis-a-vis Sensex(Chart Of The Day)

Oct 7, 2017

IPO's have failed to beat the benchmark index in the past decade.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Oct 17, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS